|
【结 构 式】 
|
【分子编号】37343 【品名】(2S)-2-([[(2S)-1-((2S,3S)-2-[[((2S)-1-[(2S,5S,8S)-20-amino-5-benzyl-2-[3-(benzyloxy)-3-oxopropyl]-8-[2-(cyclohexyloxy)-2-oxoethyl]-4,7,10,16-tetraoxo-3,6,9,15-tetraazaicos-1-anoyl]pyrrolidinyl)carbonyl]amino]-3-methylpentanoyl)pyrrolidinyl]carbonyl]amino)-4-methylpentanoic acid 【CA登记号】 |
【 分 子 式 】C63H93N9O14 【 分 子 量 】1200.48368 【元素组成】C 63.03% H 7.81% N 10.5% O 18.66% |
合成路线1
该中间体在本合成路线中的序号：(XXII)Then, two sequential couplings with N-Boc-5-aminopentanoic acid (XX), followed by deprotections with trifluoroacetic acid in the presence of ethyl methyl sulfide, provided peptide resins (XXI) and (XXII).
| 【1】 DiMaio, J. (National Research Council of Canada); Thrombin inhibitors based on the amino acid sequence of hirudin. JP 1999502203; WO 9629347 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XIX) | 37340 | (2S)-2-[[((2S)-1-[(2S,3S)-2-[([(2S)-1-[(2S)-2-[((2S)-2-[[(2S)-2-amino-4-(cyclohexyloxy)-4-oxobutanoyl]amino]-3-phenylpropanoyl)amino]-5-(benzyloxy)-5-oxopentanoyl]pyrrolidinyl]carbonyl)amino]-3-methylpentanoyl]pyrrolidinyl)carbonyl]amino]-4-methylpentanoic acid | C53H75N7O12 | 详情 | 详情 | |
| (XX) | 37341 | 5-[(tert-butoxycarbonyl)amino]pentanoic acid | C10H19NO4 | 详情 | 详情 | |
| (XXI) | 37342 | (2S)-2-[[((2S)-1-[(2S,3S)-2-[([(2S)-1-[(2S)-2-[((2S)-2-[[(2S)-2-[(5-aminopentanoyl)amino]-4-(cyclohexyloxy)-4-oxobutanoyl]amino]-3-phenylpropanoyl)amino]-5-(benzyloxy)-5-oxopentanoyl]pyrrolidinyl]carbonyl)amino]-3-methylpentanoyl]pyrrolidinyl)carbonyl]amino]-4-methylpentanoic acid | C58H84N8O13 | 详情 | 详情 | |
| (XXII) | 37343 | (2S)-2-([[(2S)-1-((2S,3S)-2-[[((2S)-1-[(2S,5S,8S)-20-amino-5-benzyl-2-[3-(benzyloxy)-3-oxopropyl]-8-[2-(cyclohexyloxy)-2-oxoethyl]-4,7,10,16-tetraoxo-3,6,9,15-tetraazaicos-1-anoyl]pyrrolidinyl)carbonyl]amino]-3-methylpentanoyl)pyrrolidinyl]carbonyl]amino)-4-methylpentanoic acid | C63H93N9O14 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XXII)Amino acid (VI) was then coupled to the peptide sequence to provide, after trifluoroacetic acid deprotection, resin (XXIII). The terminal D-Phe and L-Pro residues were incorporated as the preformed dipeptide (XXIV). Finally, cleavage of all protecting groups by means of HF in the presence of dimethyl sulfide and anisole furnished the title compound.
| 【1】 DiMaio, J. (National Research Council of Canada); Thrombin inhibitors based on the amino acid sequence of hirudin. JP 1999502203; WO 9629347 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VI) | 37333 | (7S)-7-[(tert-butoxycarbonyl)amino]-10-[(imino[[(4-methylphenyl)sulfonyl]amino]methyl)amino]-6-oxodecanoic acid | C23H36N4O7S | 详情 | 详情 | |
| (XXII) | 37343 | (2S)-2-([[(2S)-1-((2S,3S)-2-[[((2S)-1-[(2S,5S,8S)-20-amino-5-benzyl-2-[3-(benzyloxy)-3-oxopropyl]-8-[2-(cyclohexyloxy)-2-oxoethyl]-4,7,10,16-tetraoxo-3,6,9,15-tetraazaicos-1-anoyl]pyrrolidinyl)carbonyl]amino]-3-methylpentanoyl)pyrrolidinyl]carbonyl]amino)-4-methylpentanoic acid | C63H93N9O14 | 详情 | 详情 | |
| (XXIII) | 37344 | (2S)-2-[([(2S)-1-[(2S,3S)-2-([[(2S)-1-((2S,5S,8S,28S)-28-amino-5-benzyl-2-[3-(benzyloxy)-3-oxopropyl]-8-[2-(cyclohexyloxy)-2-oxoethyl]-33-imino-33-[[(4-methylphenyl)sulfonyl]amino]-4,7,10,16,22,27-hexaoxo-3,6,9,15,21,32-hexaazatritriacont-1-anoyl)pyrrolidinyl]carbonyl]amino)-3-methylpentanoyl]pyrrolidinyl]carbonyl)amino]-4-methylpentanoic acid | C81H119N13O18S | 详情 | 详情 | |
| (XXIV) | 28932 | (2S)-1-[(2R)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]-2-pyrrolidinecarboxylic acid | C19H26N2O5 | 详情 | 详情 |